To control your blood sugar, you need to replace or supplement the function of your pancreas with regular insulin injections. Long-acting insulins don’t peak like short-acting insulins — they ...

Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

Types of insulin include rapid-, regular-, intermediate-, and long-acting, based on how long they ... formulations that may vary the onset, peak, or duration.

Trials including commercially available formulations of insulin detemir or insulin glargine were compared with NPH. Pertinent English-language clinical trials published between 2000 and 2006 were ...

Merilog marks the third insulin biosimilar to receive FDA approval, following the greenlight of two long-acting biosimilar insulin products in 2021. Diabetes, a chronic disease impacting more than ...

It is the first biosimilar of a rapid-acting insulin product – used to control the blood glucose spike after meals – and only the third insulin biosimilar to be approved in the US. Novo ...

The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got US approval late last year. [caption id ...